Examining the Longitudinal Relationship Between Olfactory Dysfunction and Frailty in Community‐Dwelling, older US Adults
Otolaryngology–Head and Neck Surgery · 2024-07 · 171 (1) · 261-268
DOI: 10.1002/ohn.685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, online erschienen am 25.04.2024. Verfasst von Esther Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Olfaction Disorders, Independent Living, Frailty. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: NIA NIH HHS.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Objective
Olfactory dysfunction is a “canary in the coalmine” for aging conditions. We evaluated olfactory dysfunction as a biomarker of early frailty in older adults living in the United States. Study Design Prospective, longitudinal, nationally representative study.
Setting
National Social Life, Health and Aging Project (NSHAP).
Methods
We examined data from 1061 community‐dwelling older US adults. Odor identification (5‐item Sniffin' Stick) and frailty scores were measured at baseline and 5‐year follow‐up. Multivariate logistic regressions evaluated the association between olfactory dysfunction and frailty at baseline in cross‐section and over time in the transition from robust to prefrail to frail, adjusting for confounding factors measured at baseline.
Results
Older US adults who were anosmic at baseline were more likely to be frail 5 years later compared to normosmic peers (odds ratio [OR]: 3.83, 95% confidence interval [CI]: 1.10‐13.31, P = .035). Examining changes in frailty stage over time, we found that anosmics were more likely to transition from prefrail to frail over 5 years (OR: 3.25, 95% CI: 1.31‐8.08, P = .011). Interestingly, hyposmics did not show a similar trajectory toward frailty ( P > .05). In contrast, olfactory dysfunction was not associated with frailty in cross‐section (OR: 0.90, 95% CI: 0.43‐1.89, P = .787, hyposmia; OR: 0.72, 95% CI: 0.15‐3.35, P = .673, anosmia).
Conclusion
Older US adults with anosmia face higher odds of becoming frail over 5 years, especially those in the prefrail stage. Olfactory dysfunction may serve as a surrogate marker for early‐stage neurodegenerative diseases, which are strong contributors to frailty.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA.
- Department of Public Health Sciences, The University of Chicago, Chicago, Illinois, USA.
- Department of Psychology, The Institute for Mind and Biology, The University of Chicago, Chicago, Illinois, USA.
- Divisions of Geriatrics and Pulmonary, Critical Care, Allergy and Sleep Medicine, The University of California, San Francisco, San Francisco, California, USA.
- Department of Surgery, Section of Otolaryngology, The University of Chicago Medicine, Chicago, Illinois, USA.
ORCID-Profile: Esther Wang
Förderung
- NIA NIH HHS
Zitieren
APA
Wang, E., Wroblewski, K. E., McClintock, M. K., Witt, L. J., & Pinto, J. M. (2024). Examining the Longitudinal Relationship Between Olfactory Dysfunction and Frailty in Community‐Dwelling, older US Adults. Otolaryngology–Head and Neck Surgery, 171(1), 261-268. https://doi.org/10.1002/ohn.685
Vancouver
Wang E, Wroblewski KE, McClintock MK, Witt LJ, Pinto JM. Examining the Longitudinal Relationship Between Olfactory Dysfunction and Frailty in Community‐Dwelling, older US Adults. Otolaryngology–Head and Neck Surgery. 2024;171(1):261-268. doi:10.1002/ohn.685
BibTeX
@article{Wang2024,
author = {Wang, Esther and Wroblewski, Kristen E and McClintock, Martha K and Witt, Leah J and Pinto, Jayant M},
title = {Examining the Longitudinal Relationship Between Olfactory Dysfunction and Frailty in Community‐Dwelling, older US Adults},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2024},
volume = {171},
number = {1},
pages = {261--268},
doi = {10.1002/ohn.685}
}
EUVIMED